The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer
Status:
Terminated
Trial end date:
1990-03-01
Target enrollment:
Participant gender:
Summary
To determine the safety and toxicity of high-dose systemic methotrexate (MTX) and
dexamethasone (DEX) combined with zidovudine (AZT) and brain irradiation in patients with
AIDS-related primary central nervous system (CNS) lymphoma and to determine response rates
and survival of treated patients. Also to determine if the treatment inhibits HIV replication
in patients who are HIV culture and/or antigen positive and to assess the incidence of
opportunistic infection in these patients Results of radiation given to patients with
AIDS-related high-grade CNS lymphoma have been disappointing, with short survival times due
to infection complications. However, complete response has been documented after radiation in
some patients. High-dose MTX will be used to improve the possibility of a greater
antineoplastic response than that obtained by radiation alone. Since the underlying
immunodeficiency state is not affected by therapy directed against the lymphoma, patients are
still prone to life-threatening opportunistic infections or relapse of lymphomatous disease
within the CNS. Accordingly, AZT will also be used in an attempt to alter the overall natural
history of the disease.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)